← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Stingray Therapeutics, Inc.
Houston, TX
$3,457,194
Total funding
1
Grants
Funding over time
peak $1.5M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$3,457,194 · 1
By mechanism
R44$3,457,194 · 1
Investigators at Stingray Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
A Phase 1-2 clinical program for the teatment of Microsatellite Stable Colorectal Cancer with the combination of SR-8541A, Botensilimab, and Balstilimab$1,460,952
R44 · FY2025 · CA
Development of a potent and selective oral ENPP1 inhibitor for oncology$1,160,011
R44 · FY2022 · CA
Development of a potent and selective oral ENPP1 inhibitor for oncology$836,231
R44 · FY2023 · CA